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nonspecific, with no identifiable risk factors. All age groups
are susceptible to be infected, although the mean age was
reported 37 years, according to a recent review.4 Itraconazole,
and orally taken voric
scribed for 6 months.
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Abstract: Introduction: Basidiobolomycosis is an unusual fungal
disease that rarely involves the visceral organs such as gastrointestinal
tract. Gastrointestinal basidiobolomycosis (GIB) has been increasingly
reported in the literature, and it is an emerging disease from arid regions
worldwide, in particular, the south-western Saudi Arabia. We report a
case of GIB in a 36-year-old Saudi Arabian male patient showing
resistance to itraconazole and best treated with voriconazole. Computed
tomography showed diffusely thickened small bowel with edematous
change.
Conclusions: As GIB presents diagnostic challenges due to lack of
specific features, this case emphasizes the importance of considering
GIB in the differential diagnosis in patients presenting with fever,
abdominal pain with fast-growing abdominal mass.
(Medicine 94(35):e1430)
Abbreviations: CT = computed tomography, ESR = erythrocyte
sedimentation rate, GIB = Gastrointestinal basidiobolomycosis.
INTRODUCTION
B asidiobolomycosis is a rare fungal infection caused byBasidiobolus ranarum, a member of the subphylum Ento-
mopthoromycotina, previously included in the Zygomycete
class.1 Visceral involvement by basidiobolomycosis is rare with
the first case of gastrointestinal basidiobolomycosis (GIB)
reported in 1964.2 Only 73 cases of GIB have been reported
in the medical literature so far.3,4 The most common presenting
symptom is abdominal pain, followed by fever, weight loss, or
abdominal mass.4
Diagnosis of GIB is clinically difficult due to the fact that
GIB occurs in immunocompetent patients and so it may not be
clinically suspected.4 Furthermore, its clinical presentation isKhan, MBBS, Ibra , MSc,
Akram Awad, BSc, and Zhonghua Sun, PHD
an antifungal agent is the most common drug used to treat GIB.
We present a case of GIB showing resistance to itraconazole but
susceptible to voriconazole, another effective antifungal agent but
less commonly used in clinical practice. We emphasize the
importance of considering GIB in differential diagnosis when
dealing with patients presenting with fever and abdominal pain.
CASE REPORT
Written informed consent was obtained from the patient
for the publication of this case and accompanying images.
A 36-year-old male patient living in the Gazan region of
Saudi Arabia was admitted in the surgical unit of Khamis
Mushayet hospital 1 year ago due to suspected appendicitis.
During the surgery, a cecal mass was detected and right hemi-
colectomy with ileostomy was done. Histopathology revealed
gastrointestinal basidiobolomycosis caused by B. ranarum.
Antifungal drug itraconazole was given twice a day to the
patient following the operation, but the patient’s condition
did not improve. It was unclear whether the infection caused
by B. ranarum was resistant to itraconazole or the patient
compliance was poor. The patient was on itraconazole for 6
months while he was still symptomatic. The decision of using
the same medicine (itraconazole) was determined through
consultation with the hospital’s senior pharmacist and medical
consultant with prolonged treatment with itraconazole con-
sidered the best option.
He was readmitted for chronic fever and abdominal pain
for 6 months. We suspected intestinal obstruction. There was no
history of vomiting, melena, or rectal bleeding. Apart from a
temperature of 38.48C and ileostomy in situ, there was leuko-
cytosis (16000 mm3), eosinophilia count (18%), and raised
erythrocyte sedimentation rate (90 mm/L) (ESR). Other labora-
tory analyses such as urea nitrogen, serum creatinine, and liver
function test were within normal range. Noncontrast and con-
trast-enhanced abdominal computed tomography (CT) scans
showed generalized markedly thickened wall of the small bowel
with edematous changes (Figure 1).
Voriconazole was planned for the patient in a dose of
200 mg (intravenously). The rationale for choosing voricona-
zole is that it is proved to be a very effective antifungal drug in
the treatment of rare fungal infections or those infections
showing resistance to other antifungal agents.5,6 The treatment
with voriconazole was continued for 2 weeks and the general
condition of the patient improved. The fever subsided on the 5th
day of commencement of treatment. Leukocyte (13300 mm3)
and eosinophil counts (9%) dropped after 1 week of initiation of
voriconazole. The patient was discharged at the end of 2 weeksonazole 200 mg twice a day was pre-
The patient was advised to attend the
ic on a fortnightly basis to monitor the
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FIGURE 1. A: Non-contrast CT shows diffuse swelling of the small
bowel. B: Contrast-enhanced CT reveals the wall thickening in the
small bowel due to inflammatory changes. CT¼computed
AL-Naemi et alpatient for potential complications such as blindness and cardiac
ischemia associated with voriconazole. So far the patient was
reviewed twice in the outpatient department with subsidence of
the clinical symptoms and no complications.
DISCUSSION
Gastrointestinal basidiobolomycosis is an unusual fungal
infection of the gastrointestinal tract caused by B. ranarum. It is
rarely reported in the medical literature although sporadic cases
have been reported worldwide, predominantly in the United
States and Saudi Arabia, with some additional cases observed in
Brazil and Iran.4,7–10 Recently, this disease has become increas-
ingly recognized with 73 cases reported in the literature.3,4
Diagnosis of GIB is difficult as its occurrence in immunocom-
petent host is a cofounder. In addition, the nonspecific clinical
presentations, such as fever, abdominal pain, or abdominal
mass, could mimic infectious gastrointestinal tract disease or
tumors.11–14
Flick et al reviewed the CT images of patients diagnosed
with GIB and reported that colorectal mass is the most common
finding, followed by hepatic mass or small bowel mass.3 Bowel
wall thickening was noticed in 25% of the reported cases,
whereas bowel perforation or abscess was less commonly seen.
The abdominal mass detected by CT in GIB patients is usually
tomography.mistaken for neoplasm or inflammatory bowel disease. Sim-
ilarly in our patient the initial diagnosis was appendicitis and
the cecal mass was noticed only during the surgery. As
2 | www.md-journal.comsuggested by Flick et al, GIB should be considered in patients
presenting with a fast-growing abdominal mass. Another use-
ful clue is the failure of nonantifungal medical treatment in
such patients.
Surgical resection of the infected tissue coupled with
prolonged treatment with itraconazole appears to be the best
available clinical option. As patients treated with itraconazole
showed complete resolution of the infection in most of the
reported cases, Khan et al had questioned the use of surgical
intervention.15 Al Saleem et al avoided surgical intervention in
the management of their case with patient showing excellent
response to orally administered voriconazole.14 They suggested
that the option of choosing surgery is determined by the nature
of the disease and its location, extension, and the patient’s
condition. It is well known that itraconazole is the most fre-
quently used antifungal agent (73%), followed by amphotericin
(22%), ketoconazole (8%), and voriconazole (5%).4,7 Of these
antifungal agents, voriconazole is a valuable and generally well-
tolerated drug for the treatment of rare fungal infections and
infections resistant to other antifungal agents.5 Findings in this
case report highlight the use of voriconazole as an alternative
option in patients with no effective outcomes after being treated
with other antifungal drugs.
In conclusion, we present a case of gastrointestinal basi-
diobolomycosis with abdominal pain and mass as the initial
presenting symptoms. Although diagnosis is confirmed by
histopathology after surgical removal of the mass in the gastro-
intestinal tract, the antifungal treatment using itraconazole is not
effective. Use of voriconazole in this case shows significant
improvement of the clinical symptoms. Findings of this case
report could assist clinicians to better manage patients with
gastrointestinal basidiobolomycosis with the aim of avoiding
any complications associated with this rare disease.
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